Molecular structure of cimetidine
Find information on thousands of medical conditions and prescription drugs.


Cimetidine is a histamine H2-receptor antagonist that inhibits the production of acid in the stomach. It is largely used in the treatment of heartburn and peptic ulcers. It is marketed by GlaxoSmithKline under the trade name Tagamet®, and was approved by the Food & Drug Administration for prescriptions starting January 1, 1979. more...

Theostat 80
Thiopental sodium
Tranexamic acid
Triamcinolone hexacetonide
Tubocurarine chloride

Clinical Use

History and development

Cimetidine was the prototypical histamine H2-receptor antagonist from which the later members of the class were developed. Cimetidine was the culmination of a project at Smith, Kline & French (SK&F; now GlaxoSmithKline) to develop a histamine receptor antagonist to suppress stomach acid secretion.

At the time (1964) it was known that histamine was able to stimulate the secretion of stomach acid, but also that traditional antihistamines had no effect on acid production. In the process, the SK&F scientists also proved the existence of histamine H2-receptors.

The SK&F team used a rational drug-design structure starting from the structure of histamine - the only design lead, since nothing was known of the then hypothetical H2-receptor. Hundreds of modified compounds were synthesised in an effort to develop a model of the receptor. The first breakthrough was Nα-guanylhistamine, a partial H2-receptor antagonist. From this lead the receptor model was further refined and eventually led to the development of burimamide - the first H2-receptor antagonist. Burimamide, a specific competitive antagonist at the H2-receptor 100-times more potent than Nα-guanylhistamine, proved the existence of the H2-receptor.

Burimamide was still insufficiently potent for oral administration and further modification of the structure, based on modifying the pKa of the compound, lead to the development of metiamide. Metiamide was an effective agent, however it was associated with unacceptable nephrotoxicity and agranulocytosis. It was proposed that the toxicity arose from the thiourea group, and similar guanidine-analogues were investigated until the ultimate discovery of cimetidine.


Cimetidine is a known inhibitor of many isozymes of the cytochrome P450 enzyme system (specifically CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). This inhibition forms the basis of the numerous drug interactions that occur between cimetidine and other drugs. For example, cimetidine may decrease metabolism of some drugs, such as oral contraceptives.

Adverse drug reactions were also found to be relatively common with cimetidine.

The development of longer-acting H2-receptor antagonists with reduced adverse effects such as ranitidine proved to be the downfall of cimetidine and, whilst it is still used, it is no longer amongst the more widely used H2-receptor antagonists.


[List your site here Free!]

Management of acute renal failure
From American Family Physician, 11/1/05 by Eddie Needham

Acute renal failure is present in 1 to 5 percent of patients at hospital admission and affects up to 20 percent of patients in intensive care units. The condition has prerenal, intrarenal, and postrenal causes, with prerenal conditions accounting for 60 to 70 percent of cases. The cause of acute renal failure usually can be identified through an appropriate history, a physical examination, and selected laboratory tests. The initial laboratory evaluation should include urinalysis, a determination of the fractional excretion of sodium, a blood urea nitrogen to creatinine ratio, and a basic metabolic panel. Management includes correction of fluid and electrolyte levels; avoidance of nephrotoxins; and kidney replacement therapy, when appropriate. Several recent studies support the use of acetylcysteine for the prevention of acute renal failure in patients undergoing various procedures. The relative risk of serum creatinine elevation was 0.11 in patients undergoing radiocontrast-media procedures (absolute risk reduction: 19 percent) and 0.33 in patients undergoing coronary angiography (absolute risk reduction: 8 percent). In patients pretreated with sodium bicarbonate before radiocontrast-media procedures, the relative risk of serum creatinine elevation was 0.13 and the absolute risk reduction was 11.9 percent. Dopamine and diuretics have been shown to be ineffective in ameliorating the course of acute renal failure.


Acute renal failure is an acute loss of kidney function that occurs over days to weeks and results in an inability to appropriately excrete nitrogenous wastes and creatinine. Electrolyte disturbances and loss of fluid homeostasis may occur. In spite of this rapid decline in kidney function, patients with acute renal failure often have few symptoms.

A strict definition of acute renal failure is lacking. Accepted diagnostic criteria include an increase in the serum creatinine level of 0.5 mg per dL (44.2 [micro]mol per L) or a 50 percent increase in the creatinine level above the baseline value, a 50 percent decrease in the baseline-calculated glomerular filtration rate (GFR), or the need for acute kidney replacement therapy. (1-3) Oliguria is defined as a urine anuria is defined as a urine output of less than 100 mL in 24 hours.

Acute renal failure is present in 1 to 5 percent of patients at hospital admission. The condition affects 15 to 20 percent of patients in intensive care units (ICUs); reported mortality rates range from 50 to 70 percent in these patients. (1-3) Infection and cardiorespiratory complications are the most common causes of death in patients with acute renal failure.


Creatinine is a metabolic waste product excreted by the kidneys. When the GFR is normal, creatinine is filtered through the glomerulus into the tubules and then excreted. Creatinine also is secreted by tubular cells.

Medications such as trimethoprim (Proloprim; with sulfamethoxazole [Bactrim, Septra]) and cimetidine (Tagamet) can inhibit tubular secretion and falsely elevate the serum creatinine level. (2) Formulas to estimate the GFR in patients with acute renal failure should not be used to adjust medication dosages because the serum creatinine level is not in a steady state and continues to fluctuate. (3)

Causes of Acute Renal Failure

Traditionally, the causes of acute renal failure are classified as prerenal, intrarenal, or postrenal (Table 1). (3)


Prerenal causes of acute renal failure are common, with intravascular volume depletion being the most common cause. (4) Fever, vomiting, and diarrhea can lead to decreased kidney perfusion. Dehydration from any cause, including diuretics, can precipitate acute renal failure.

Prerenal azotemia occurs in diseases that lead to a decrease in the effective arterial blood volume. These diseases include heart failure, liver failure, and nephrotic syndrome.

Nonsteroidal anti-inflammatory drugs (NSAIDs) and angiotensin-converting enzyme (ACE) inhibitors are known to cause prerenal azotemia. NSAIDs affect the kidney by blocking cyclo-oxygenase, leading to an increase in thromboxane [A.sub.2], which is a potent vasoconstrictor of the preglomerular arterioles. Because these afferent vessels supply blood to the kidney, vasoconstriction causes decreased glomerular perfusion. (5)

ACE inhibitors block the production of angiotensin II, causing vasodilation of the postglomerular efferent arterioles. The vasodilation results in a decrease in the glomerular pressure, which may cause azotemia. (6)

Large-vessel diseases, such as thrombosis, embolus, and dissection, also can reduce renal perfusion.


Intrarenal causes of acute renal failure are classified as tubular, glomerular, interstitial, and vascular.

Injury to the tubules most often is caused by ischemia or nephrotoxins. If prerenal azotemia and poor perfusion continue without treatment, tubular cells begin to die. This condition is termed "acute tubular necrosis." Acute tubular necrosis is not a separate entity; rather, it is a marker of a more severe ischemic insult to the kidneys. Therefore, prerenal azotemia and tubular ischemia represent stages in the continuum of tubular injury. (1,7)

Acute tubular necrosis has three phases: initiation, maintenance, and recovery. After the initial insult to the kidneys, the maintenance phase typically lasts one to two weeks. During the recovery phase, there may be marked diuresis and a slow return of kidney function. To date, no therapy has been shown to hasten recovery from acute tubular necrosis.

Efforts should be made to prevent the development of acute tubular necrosis in high-risk patients. Conditions that place patients at risk for this condition include untreated prerenal azotemia and the use of nephrotoxic drugs or exposure to other nephrotoxins (Table 2).

Glomerulonephritis, an uncommon cause of acute renal failure, has systemic manifestations such as fever, rash, and arthritis. Urine findings include red blood cell casts, hematuria, and proteinuria. It is important to evaluate all patients with glomerulonephritis for diseases such as systemic lupus erythematosus. Consultation with a nephrologist may be required; renal biopsy may be necessary.

Acute interstitial nephritis is an interstitial disturbance that leads to acute renal failure. (The diagnosis and management of this condition have been reviewed in American Family Physician. (8)) Acute interstitial nephritis often results from an allergic reaction to a drug (Table 3). Symptoms include fever and rash. Serum and urine eosinophil counts may be elevated. Autoimmune diseases, infection, and infiltrative diseases also can lead to interstitial nephritis. If a drug is suspected as the causative agent, immediate withdrawal of the drug and supportive care are essential. Corticosteroids may be beneficial. (9,10)

Vascular disease can occur on the microvascular and macrovascular levels. Depending on the location of the lesion(s), vascular causes can be prerenal or intrarenal. Microvascular processes commonly present as micro-angiopathic hemolytic anemia and acute renal failure secondary to small-vessel thrombosis or occlusion. Macrovascular causes of acute renal failure should be suspected in older patients. These causes include renal artery stenosis or thrombosis, atheroembolism secondary to atrial fibrillation, and aortic disease or acute dissection. (11)


Postrenal causes of acute renal failure result in obstruction of the outflow tracts of the kidneys. Causes include prostatic hypertrophy, catheters, tumors, strictures, and crystals. Neurogenic bladder also can cause an obstruction.

Because postrenal causes are readily reversible, it is imperative to exclude them. (12) Recovery of renal function is directly proportional to the duration of the obstruction. Renal ultrasonography can be used to assess patients for hydronephrosis. Because no contrast dye is used, renal function is not further compromised.

Identification of Probable Causes

Probable causes of acute renal failure, based on the findings of the history, are listed in Table 4. (13) Probable causes based on the physical findings are listed in Table 5. (13) Urine test values and serum creatinine levels in prerenal and intrarenal acute renal failure are compared in Table 6. (2,3,7,13) Selected diagnostic test results and their interpretations are given in Table 7. (13)

Urine collected before the initiation of intravenous fluid or diuretic treatment can be used to calculate the fractional excretion of sodium (FENa). The first urine sample obtained from the patient in the emergency department is the most useful. In a patient with acute renal failure, a FENa below 1 percent reflects preservation of the sodium and water. A FENa higher than 1 percent suggests the presence of acute tubular necrosis and loss of the kidneys' ability to concentrate urine.


Acute renal failure often is preventable. Risk factors for this condition include diabetes mellitus, chronic renal insufficiency, heart failure, and advanced age.

Many medications can injure the kidneys. Dosing schedules can help prevent acute renal failure. For example, acute renal failure is less likely to develop with a once-daily dose of an aminoglycoside than with multiple daily doses. (14)

When acute renal failure is diagnosed, the cause(s) must be identified and treated (Figure 1). Critical measures include maintaining adequate intravascular volume and mean arterial pressure, discontinuing all nephrotoxic drugs, and eliminating exposure to any other nephrotoxins (Table 2). (13) Electrolyte abnormalities must be corrected, and urine output should be monitored closely. Pigment or uric acid exposure can be treated with alkaline diuresis. Ethylene glycol or methanol poisoning should be treated with an alcohol drip or with fomepizole (Antizol). (15,16)


Hyperkalemia is a common complication of acute renal failure. (17) Potassium levels below 6 mEq per L (6 mmol per L) usually can be managed with dietary restriction and resin binders. Caloric intake should come primarily from carbohydrates. Protein intake should be balanced to minimize nitrogenous waste production while limiting starvation ketosis and subsequent production of ketoacids. This balance is achieved best with a protein intake of 0.6 g per kg per day.

Sodium bicarbonate therapy should be reserved for the treatment of severe metabolic acidosis (i.e., pH below 7.2 or a bicarbonate level below 10 to 15 mEq per dL [10 to 15 mmol per L]) with or without associated hyperkalemia. It is important to note that sodium bicarbonate and sodium polystyrene sulfonate have a large sodium load and may worsen fluid status in patients with acute renal failure.

When hyperkalemia is severe and unresponsive to treatment, kidney replacement therapy may be indicated (Table 8). (1-4,18) The use of intermittent or continuous hemodialysis (multiple techniques) continues to be debated. Both approaches are effective, and studies have not demonstrated either approach to be superior to the other. (18,19) Intermittent hemodialysis requires less anticoagulation than does continuous hemodialysis; however continuous hemodialysis can be performed in patients with less hemodynamic stability.

Although renal biopsy rarely is performed, it may be indicated for patients with acute renal failure who do not respond to therapy or for assistance in the diagnosis of glomerulonephritis.

Future directions


Evidence exists that the prophylactic use of acetylcysteine (Mucomyst) before radiocontrast-media procedures decreases the incidence of acute renal failure. (20,21)

In one randomized trial (20) of 83 patients with chronic renal insufficiency, patients were assigned to receive 0.45 percent saline plus oral acetylcysteine (600 mg twice daily) or 0.45 percent saline alone before undergoing computed tomographic scanning. Within 48 hours after the imaging test, creatinine levels increased by 0.5 mg per dL or more in nine of the 42 patients in the saline-only group but increased in just one of the 41 patients in the acetylcysteine group (P = .01, relative risk = 0.11, absolute risk reduction = 19%, number needed to treat = 5).

A second randomized controlled trial (21 evaluated acetylcysteine pretreatment in patients scheduled to undergo coronary angiography and angioplasty. All patients had stable, moderate renal insufficiency and a GFR of less than 60 mL per minute. Patients randomly received acetylcysteine (600 mg twice daily) the day before the coronary procedure and the day of the procedure. All patients received an infusion of 0.9 percent normal saline. Within 48 hours of the procedure, serum creatinine levels increased by more than 25 percent in 12 of 98 patients in the saline-only group and in four of 102 patients in the acetylcysteine group (P = 0.03, relative risk = 0.33, absolute risk reduction = 8%, number needed to treat = 12).

A third study (22) showed that preprocedural acetylcysteine was neither helpful nor harmful.


Dopamine traditionally has been used to promote renal perfusion. However, systematic reviews (23-25) of dopamine treatment in critically ill patients and in patients with sepsis do not support the use of dopamine to prevent renal insufficiency, morbidity, or mortality.

A multicenter, randomized, double-blind, placebo-controlled trial (23) of low-dose dopamine therapy was conducted in patients with clinical evidence of early renal dysfunction who met two criteria for systemic inflammatory response syndrome (sepsis). In this study, 328 patients from 23 ICUs were assigned to receive dopamine (2 mcg per kg per minute) or placebo. The primary endpoint was elevation of the serum creatinine level during the infusion. No statistical differences were found between the two groups in elevation of creatinine levels, need for dialysis, duration of ICU stay, or length of hospital stay. There were 69 deaths in the dopamine group and 66 deaths in the placebo group. The study showed no benefit for dopamine.

A recent meta-analysis (24) was conducted on the use of dopamine to reduce the incidence or severity of acute renal failure, the need for dialysis, or mortality in critically ill patients. Of the 58 studies that were identified, 17 were randomized clinical trials. Dopamine did not prevent mortality, onset of acute renal failure, or need for dialysis. A literature review (25) reached a similar conclusion.


Historically, nonoliguric renal failure has been assumed to have a better outcome than oliguric renal failure. As a result, diuretics commonly have been given in an attempt to convert the oliguric state to a nonoliguric state. How ever, diuretics have not been shown to be beneficial, and they may worsen outcomes. (26)

An observational study (27) of 552 patients with acute renal failure in four ICUs found that 326 of the patients were given diuretics at the time of nephrology consultation. The patients initially given diuretics were older; were more likely to have a lower serum blood urea nitrogen concentration; and were more likely to have a history of heart failure, nephrotoxic renal failure, or acute respiratory failure. The main outcome measures were all-cause hospital mortality, nonrecovery of renal function, or both. Diuretic use in these higher risk patients was associated with a significant risk of death or nonrecovery of renal function (odds ratio [OR] = 1.77; 95% confidence interval [CI] = 1.14 to 2.76). In the patients who survived one week past the initial nephrology consultation, the risk of death and nonrecovery of renal function was significantly increased (OR = 3.12;95% CI = 1.73 to 5.62).


A recent placebo-controlled trial (28) involving 119 patients found an absolute risk reduction of 11.9 percent and a relative risk of 0.13 for elevated serum creatinine levels (from contrast-induced nephropathy) in patients who were given a sodium bicarbonate infusion before a radiocontrast-media procedure compared with those who were given only saline. This single-center study was stopped early because of the degree of benefit demonstrated for sodium bicarbonate infusion. Author disclosure: Nothing to disclose.


(1.) Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.

(2.) Albright RC Jr. Acute renal failure: a practical update. Mayo Clin Proc 2001;76:67-74.

(3.) Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA 2003;289: 747-51.

(4.) Star RA. Treatment of acute renal failure. Kidney Int 1998;54:1817-31.

(5.) Venturini CM, Isakson P, Needleman P. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Curr Opin Nephrol Hypertens 1998;7:7982.

(6.) Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985-91.

(7.) Brady H, Brenner B. Acute renal failure. In: Kasper DL, et al., eds. Harrison's Principles of internal medicine. 16th ed. New York: McGraw Hill, 2001:1644-53.

(8.) Kodner CM, Kudrimoti A. Diagnosis and management of acute interstitial nephritis. Am Fam Physician 2003;67:2527-34.

(9.) Galpin JE, Shinaberger JH, Stanley TM, Blumenkrantz MJ, Bayer AS, Friedman GS, et al. Acute interstitial nephritis due to methicillin. Am J Med 1978;65:756-65.

(10.) Pusey CD, Saltissi D, Bloodworth L, Rainford DJ, Christie JL. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983;52:194-211.

(11.) Abuelo JG. Diagnosing vascular causes of renal failure [published correction appears in Ann Intern Med 1995;124(pt 1):78]. Ann Intern Med 1995;123:601-14.

(12.) Martinez-Maldonado M, Kumjian DA. Acute renal failure due to urinary tract obstruction. Med Clin North Am 1990;74:919-32.

(13.) Agrawal M, Swartz R. Acute renal failure [published correction appears in Am Fam Physician 2001;63:445]. Am Fam Physician 2000;61:2077-88.

(14.) Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.

(15.) Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group. N Engl J Med 1999;340:832-8.

(16.) Brent J, McMartin K, Phillips S, Aaron C, Kulig K; Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001;344:424-9.

(17.) Green GB, Coyne D. Renal disease. In: Green GB, Harris IS, Lin GA, Moylan KC, eds. The Washington manual of medical therapeutics. 31st ed. Philadelphia: Lippincott Williams & Wilkins, 2004:252-71.

(18.) Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, et al.; Collaborative Group for Treatment of ARF in the ICU. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 2001;60:1154-63.

(19.) Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051-8.

(20.) Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.

(21.) Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, et al. Acetylcys-teine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003;289;553-8.

(22.) Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.

(23.) Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-43.

(24.) Kellum JA, Decker MJ. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-31.

(25.) Denton MD, Chertow GM, Brady HR. "Renal-dose" dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996;50:4-14.

(26.) Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL. Highdose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004;44:4029.

(27.) Mehta RL, Pascual MT, Soroko S, Chertow GM; PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547-53.

(28.) Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:232-834.

Oliguria is defined as a urine output of less than 400 mL in 24 hours, and anuria is defined as a urine output of less than 100 mL in 24 hours.

EDDIE NEEDHAM, M.D., is assistant professor of family medicine and program director of the family medicine residency program at Emory University School of Medicine, Atlanta. Dr. Needham received his medical degree from Emory University School of Medicine and completed a family medicine residency at Tripler Army Medical Center, Honolulu. He is a fellow of the American Academy of Family Physicians.

Address correspondence to Eddie Needham, M.D., Emory University School of Medicine, 4575 N. Shallowford Rd., Atlanta, GA 30338. Reprints are not available from the author.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Tagamet
Home Contact Resources Exchange Links ebay